



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

<b>INFORMATION DISCLOSURE STATEMENT</b>		Docket Number <b>11957/62</b>	
Application Number <b>10/765,236</b>	Filing Date <b>January 26, 2004</b>	Examiner <b>Not Yet Assigned</b>	Art Unit <b>Not Yet Assigned</b>
Invention Title <b>COMPOSITION AND METHOD FOR LOWERING RISK FACTORS OF CARDIOVASCULAR DISEASE</b>		Inventor(s) <b>Matthias RATH</b>	

Address to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date:

Signature:

Siu K. Lo


(Reg. No. 46,877)

SIR:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 that was cited in the parent application (App. Ser. No. 09/970,609 now USP 6,693,129) is not enclosed; however, two references listed in "Other Documents" of Kennedy and Dardik, at Items A and B, are enclosed herewith.
3. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).

4. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 5/11/04

By:   
Siu K. Lo (Reg. No.)  
46,877

KENYON & KENYON  
One Broadway  
New York, New York 10004  
(212)425-7200 telephone  
(212)425-5288 facsimile

**CUSTOMER NO. 26646**

© Kenyon & Kenyon 2004



**INFORMATION DISCLOSURE  
STATEMENT BY  
APPLICANTS  
PTO FORM 1449**

Atty. Docket No.  
**11957/62**

Serial No.  
**10/765,236**

Applicant(s)  
**Rath**

Filing Date  
**January 26, 2004**

Group  
**Not Yet Assigned**

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME
	4,009,265	22 Feb 1997	Howard
	4,414,238	8 Nov 1983	Schmidt
	4,657,866	14 Apr 1987	Kumar
	4,891,220	2 Jan 1990	Donzis
	5,108,767	28 Apr 1992	Mulchandani et al.
	5,230,996	27 Jun 1993	Rath et al.
	5,268,181	7 Dec 1993	Neill et al.
	5,278,189	11 Jan 1994	Rath et al.
	5,326,569	May 7 1994	Acosta et al.
	5,332,579	26 Jul 1994	Umbdenstock
	5,650,418	22 Jul 1997	Rath et al.
	5,962,517	5 Oct 1999	Murad
	5,922,766	13 Jul 1999	Acosta et al.
	6,048,846	11 Apr 2000	Cochran
	6,245,803	12 Jun 2001	Acosta
	6,299,896	10 Sep 2001	Cooper et al.
	6,361,800	26 Mar 2002	Cooper et al.
	6,451,341	17 Sep 2002	Slaga et al.
	US-2003/0003162 A1	2 Jan 2003	Rath
	US-2002/0128309 A1	12 Sep 2002	Rath
	US-2002/0173546 A1	21 Nov 2002	Rath



## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						Yes	No
	EP 0891771 A1	20/1/1999	EPO				
	EP 1163904 A1	19/12/2001	EPO				
	EP 1195159 A1	4/10/2002	EPO				
	EP 1068868 A2	17/1/2001	EPO				
	GB 2268871 A	26/1/1994	UK				

## OTHER DOCUMENTS

EXAMINER'S INITIALS		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	<b>A</b>	Kennedy, R. <i>Lipoprotein(a), Vascular Disease, and Vitamin C</i> . The Doctor's Medial Library, <a href="http://www.medical-library.net">www.medical-library.net</a> , January 5, 1999.
	<b>B</b>	Dardik et al., <i>A Quantitative Assay for the Non-Covalent Association Between Apolipoprotein(a) and Apolipoprotein B: An Alternative Measure of Lp(a) Assembly</i> . Journal of Lipid Research, Volume 41, 2000, esp. p. 1018, para 4.
	<b>C</b>	<i>Life Extension Mix Multivitamin</i> , Product Information Brochure, <a href="http://www.iberb.com">www.iberb.com</a> , 1997.
	<b>D</b>	<i>Multi Li Caps</i> , Product Information Brochure, <a href="http://www.solgar.com">www.solgar.com</a> , 1996.
	<b>E</b>	<i>Mega Vita-Min</i> , Product Information Brochure, <a href="http://www.naturesbounty.com">www.naturesbounty.com</a> , 2000.
	<b>F</b>	Vinson, Joe A, et al., <i>A Citrus Extract Plus Ascorbic Acid Decreases Lipids, Lipid Peroxides, Lipoprotein Oxidative Susceptibility, and Atherosclerosis in Hypercholesterolemic Hamsters</i> , J. Agric. Food Chem, Vol. 46, pp. 1453-1459, 1998.
	<b>G</b>	Giroux, Isabelle et al., <i>Role of dietary lysine, methionine, and arginine in the regulation of hypercholesterolemia in rabbits</i> , J. Nutr. Biochem., Vol. 10, pp. 166-171, 1991.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	